Device Delivers Drugs Straight to the Heart
News Jun 12, 2018 | Original story by Leah Burrows for Harvard University
Therepi looks like a small patch and can be sutured onto tissue, in this case, a heart. Credit: Second Bay Studios/Harvard SEAS
An international team of researchers, led by Harvard University, have developed a refillable, implantable device, which sits directly on the heart and can deliver drugs and other therapies to treat the aftereffects of a heart attack.
The device, dubbed Therepi, is a small patch that is sutured onto the heart. The patch contains a sponge-like biomaterial that holds and releases therapies through the permeable surface of the device. The biomaterial can be connected to a port or pump outside the body when it needs to be refilled. In a pre-clinical study, the researchers demonstrated that Therepi can increase heart function for more than four weeks when stem cells are repeatedly delivered to the reservoir.
Residual scarring after a heart attack can lead to heart failure. Different therapies, including drugs, proteins and stem cells, could treat scarring but these treatments struggle to reach or stay at their intended target and often require multiple doses to work. This device solves for those challenges by allowing localized, replenishable, tunable therapy delivery. It paves the way for other devices to deliver multiple courses of therapies directly to diseased tissue.
This article has been republished from materials provided by Harvard University. Note: material may have been edited for length and content. For further information, please contact the cited source.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.